CL Colgate-Palmolive Earnings Preview April 23

Colgate-Palmolive Company (CL) reports earnings on April 23, 2026, after market close. The $65.6 billion consumer goods giant faces investor scrutiny as it navigates pricing pressures and competition in oral care and pet nutrition. With a Meyka AI grade of A, the company shows strong fundamentals despite recent stock weakness. CL trades at $81.81, down 2.1% today but up 3.5% year-to-date. Analysts will focus on organic growth, margin expansion, and guidance for the remainder of 2026. Understanding historical earnings patterns helps investors prepare for potential surprises.

Historical Earnings Performance and Trends

Colgate-Palmolive has demonstrated consistent earnings growth over the past four quarters, with a clear upward trajectory. The company beat EPS estimates in three of the last four quarters, showing operational discipline.

Recent Quarter Results

In the most recent quarter (Q4 2025), CL reported EPS of $0.95 against an estimate of $0.912, beating by 3.8%. Revenue came in at $5.23 billion versus the estimate of $5.12 billion, a 2.1% beat. This marks the third consecutive quarter of EPS outperformance. The Q3 2025 quarter showed EPS of $0.92 against $0.897 estimated, and Q2 delivered EPS of $0.91 against $0.856 estimated.

Earnings Momentum

Year-over-year, CL’s EPS growth accelerated significantly. The company posted 26.97% EPS growth in 2024, driven by strong net income growth of 25.6%. Operating income grew 6.1%, while revenue expanded just 3.3%, indicating strong margin expansion. This operational leverage suggests management is executing well on cost control and pricing strategies despite inflationary pressures.

What to Expect: April 23 Earnings Estimates

Analyst consensus for the upcoming earnings report remains constructive, though specific EPS and revenue estimates are not yet finalized for this quarter. Based on historical patterns and company guidance, investors should monitor key performance indicators.

Analyst Consensus and Expectations

All 13 analysts covering CL rate the stock as Buy, with a consensus rating of 4.0 out of 5. This unanimous bullish stance reflects confidence in the company’s business model and execution. The lack of Hold or Sell ratings is notable in a challenging consumer staples environment. Analysts expect CL to continue delivering mid-single-digit organic growth while maintaining pricing discipline.

Beat/Miss Probability

Based on the last four quarters, CL has beaten EPS estimates 75% of the time (three of four quarters). The company’s track record suggests a high probability of beating the April 23 estimates. Management has demonstrated the ability to manage costs, optimize product mix, and pass through pricing to consumers. However, the Q4 2025 quarter was the only miss in the recent period, suggesting some volatility remains.

Key Metrics and Financial Health

Colgate-Palmolive maintains a fortress balance sheet with strong cash generation, though valuation metrics reflect market expectations.

Valuation and Profitability

CL trades at a P/E ratio of 31.1, above its 200-day average of 84.14, indicating premium valuation. The price-to-sales ratio of 3.23 is elevated for a consumer staples company. However, the company generates $5.22 operating cash flow per share and $4.52 free cash flow per share, supporting the $1.05 annual dividend and buybacks. Net profit margin stands at 10.5%, reflecting strong pricing power and operational efficiency.

Growth Drivers

Free cash flow grew 16.6% in 2024, outpacing revenue growth of 3.3%, demonstrating margin expansion. The company’s gross profit margin of 60.1% provides cushion for investments in innovation and marketing. Operating margin of 21.3% ranks among the best in consumer staples. Return on equity of 4.3% appears low but reflects the company’s high leverage and capital structure optimized for shareholder returns.

What Investors Should Watch

Several factors will determine market reaction to the April 23 earnings report and guide stock performance.

Organic Growth and Pricing

Investors should focus on organic revenue growth, which separates pricing actions from volume trends. With inflation moderating, CL’s ability to maintain pricing without volume declines will be critical. Management commentary on consumer elasticity and market share trends in key categories like toothpaste and pet nutrition will signal competitive positioning.

Segment Performance

The Oral, Personal and Home Care segment generates the majority of revenue, while Pet Nutrition (Hill’s brand) is the growth engine. Analysts will scrutinize Hill’s performance, as pet nutrition faces margin pressure from ingredient costs. Guidance for full-year 2026 organic growth, margin targets, and capital allocation plans will shape investor sentiment.

Meyka AI Grade Significance

Meyka AI rates CL with a grade of A, scoring 80.4 out of 100. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The A grade reflects strong fundamentals, consistent execution, and attractive risk-reward despite elevated valuation. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Colgate-Palmolive enters its April 23 earnings report with strong momentum and analyst support. The company’s 75% beat rate over the last four quarters and 26.97% EPS growth in 2024 suggest management is executing well. With all 13 analysts rating CL as Buy and the Meyka AI A grade reflecting solid fundamentals, the bar is set high. Investors should focus on organic growth trends, segment performance, and 2026 guidance. The stock’s 31.1 P/E ratio prices in continued execution, making earnings quality and forward guidance critical to justifying valuation. Watch for commentary on pricing elasticity and pet nutrition margins.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.